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Abstract
Background: Obesity is associated with vitamin D deficiency, and both are areas of active public health concern. We
explored the causality and direction of the relationship between body mass index (BMI) and 25-hydroxyvitamin D [25(OH)D]
using genetic markers as instrumental variables (IVs) in bi-directional Mendelian randomization (MR) analysis.
Methods and Findings: We used information from 21 adult cohorts (up to 42,024 participants) with 12 BMI-related SNPs
(combined in an allelic score) to produce an instrument for BMI and four SNPs associated with 25(OH)D (combined in two
allelic scores, separately for genes encoding its synthesis or metabolism) as an instrument for vitamin D. Regression
estimates for the IVs (allele scores) were generated within-study and pooled by meta-analysis to generate summary
effects. Associations between vitamin D scores and BMI were confirmed in the Genetic Investigation of Anthropometric
Traits (GIANT) consortium (n = 123,864). Each 1 kg/m2 higher BMI was associated with 1.15% lower 25(OH)D
(p = 6.52610227). The BMI allele score was associated both with BMI (p= 6.30610262) and 25(OH)D (20.06% [95% CI
20.10 to 20.02], p= 0.004) in the cohorts that underwent meta-analysis. The two vitamin D allele scores were strongly
associated with 25(OH)D (p#8.07610257 for both scores) but not with BMI (synthesis score, p= 0.88; metabolism score,
p= 0.08) in the meta-analysis. A 10% higher genetically instrumented BMI was associated with 4.2% lower 25(OH)D
concentrations (IV ratio: 24.2 [95% CI 27.1 to 21.3], p= 0.005). No association was seen for genetically instrumented
25(OH)D with BMI, a finding that was confirmed using data from the GIANT consortium (p$0.57 for both vitamin D scores).
Conclusions: On the basis of a bi-directional genetic approach that limits confounding, our study suggests that a higher BMI
leads to lower 25(OH)D, while any effects of lower 25(OH)D increasing BMI are likely to be small. Population level
interventions to reduce BMI are expected to decrease the prevalence of vitamin D deficiency.
Please see later in the article for the Editors’ Summary.
Citation: Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, et al. (2013) Causal Relationship between Obesity and Vitamin D Status: Bi-Directional Mendelian
Randomization Analysis of Multiple Cohorts. PLoS Med 10(2): e1001383. doi:10.1371/journal.pmed.1001383
Academic Editor: Cosetta Minelli, Centre for Biomedicine, EURAC, Italy
Received May 31, 2012; Accepted December 24, 2012; Published February 5, 2013
Copyright:  2013 Vimaleswaran et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors thank the British Heart Foundation (grant PG/09/023) and the UK Medical Research Council (MRC; grant G0601653) for funding this work.
ADH is a British Heart Foundation Senior Research Fellow (Award FS05/125). EH is a Department of Health (UK) Public Health Career Scientist. This work was
undertaken at the Centre for Paediatric Epidemiology and Biostatistics, which benefits from funding support from the MRC in its capacity as the MRC Centre of
Epidemiology for Child Health. Research at the University College London Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust
benefits from R&D funding received from the NHS Executive. No funding bodies had any role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: LTH is currently supported by a Canada Institute of Research (CIHR) Fellowship award. CC has received honoraria and consulting fees
from Amgen, Eli Lilly, Medtronic, Merck, Novartis, and Servier. WM is an employee of synlab laboratory services GmbH. Synlab offers vitamin D testing. TJW is on
the scientific advisory board for Diasorin Inc. and has received research support from them. JCW is 90% employed by GlaxoSmithKline (GSK) whilst maintaining a
10% appointment at London School of Hygiene & Tropical Medicine (LSHTM), and holds GSK shares. All other authors declare that no competing interests exist.
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; GIANT, Genetic Investigation of Anthropometric Traits; IV, instrumental variable; MR,
Mendelian randomization
* E-mail: e.hypponen@ucl.ac.uk
. These authors contributed equally to this work.
" Membership of the Genetic Investigation of Anthropometric Traits (GIANT) consortium is provided in the Acknowledgments.
Body Mass Index and 25(OH)D
PLOS Medicine | www.plosmedicine.org 2 February 2013 | Volume 10 | Issue 2 | e1001383
Introduction
The prevalence of obesity has increased in the last two decades
and it is presently the most common and costly nutritional problem
[1–4]. In the United States, one-third of the population is affected
by obesity, according to the National Health and Nutrition
Examination Survey [5]. Despite a known genetic contribution,
the increase in obesity prevalence has been largely attributed to
lifestyle changes, which means that it is amenable to modification
through public health and other interventions [6].
Vitamin D deficiency is another increasingly prevalent public
health concern in developed countries [7–9], and there is evidence
that vitamin D metabolism, storage, and action both influence and
are influenced by adiposity. Observational studies have reported
an increased risk of vitamin D deficiency in those who are obese;
however, the underlying explanations and direction of causality
are unclear [10]. Active vitamin D (1,25-dihydroxyvitamin D) may
influence the mobilisation of free fatty acids from the adipose tissue
[11]. In vitro experiments in rats have also shown that large doses
of vitamin D2 lead to increases in energy expenditure due to
uncoupling of oxidative phosphorylation in adipose tissues [12].
However, randomized controlled trials (RCTs) testing the effect of
vitamin D supplementation on weight loss in obese or overweight
individuals have provided inconsistent findings [13–15]. It has also
been suggested that obesity could result from an excessive adaptive
winter response, and that the decline in vitamin D skin synthesis
due to reduced sunlight exposure contributes to the tendency to
increase fat mass during the colder periods of the year [16,17].
However, vitamin D is stored in the adipose tissue and, hence,
perhaps the most likely explanation for the association is that the
larger storage capacity for vitamin D in obese individuals leads to
lower circulating 25-hydroxyvitamin D [25(OH)D] concentra-
tions, a marker for nutritional status [18].
In the Mendelian randomization (MR) approach, causality is
inferred from associations between genetic variants that mimic the
influence of a modifiable environmental exposure and the
outcome of interest [19]. If lower vitamin D intake/status is
causally related to obesity, a genetic variant associated with lower
25(OH)D concentrations should be associated with higher body
mass index (BMI) (in proportion to the effect on 25(OH)D).
Conversely, if obesity leads to lower vitamin D status, then genetic
variants associated with higher BMI should be related to lower
25(OH)D concentrations. The genetic associations, unlike the
directly observed associations for vitamin D intake/status, should
be less prone to confounding by lifestyle and socio-economic
factors and be free from reverse causation as genotypes are
invariant and assigned at random before conception [20]. The use
of multiple SNPs to index the intermediate exposure of interest
increases power and reduces the risk of alternative biological
pathways (pleiotropy) affecting the observed associations between
the genotype and the outcome [21,22].
In the present study, we investigated the relationship between
BMI, a commonly used measure for monitoring the prevalence of
obesity at the population level, and vitamin D status and we
inferred causality by using genetic variants as instruments in bi-
directional MR analyses. Meta-analysis included data from 21
studies comprising up to 42,024 individuals.
Methods
Ethics Statement
All participants provided written, informed consent, and ethical
permission was granted by the local research ethics committees for
all participating studies.
Participants
The collaboration investigating the association of vitamin D and
the risk of cardiovascular disease and related traits (D-CarDia)
consists of European ancestry cohorts from the United Kingdom
(UK), United States (US), Canada, Finland, Germany, and
Sweden. This study comprised a meta-analysis of directly
genotyped and imputed SNPs from 21 cohorts totalling 42,024
individuals (Table 1). An expanded description of the participating
studies is provided in the Text S2.
To replicate our findings on the association between the vitamin
D-related SNPs and allele scores with BMI, we used the data from
the genome-wide meta-analyses on BMI conducted as part of the
Genetic Investigation of Anthropometric Traits (GIANT) consor-
tium [23]. The GIANT meta-analyses consisted of 46 studies with
up to 123,865 adults of European ancestry, including the 1958
British Birth Cohort, Framingham Heart study, Nurses’ Health
Study, Twins UK, UK Blood Services Common Control
Collection, the Amish Family Osteoporosis Study, Health2000
GENMETS sub-sample, and Northern Finland Birth Cohort
1966, which were also part of the D-CarDia collaboration.
Genotyping
We selected 12 established BMI-related SNPs (fat mass and
obesity-associated, [FTO]- rs9939609, melanocortin 4 receptor
[MC4R]- rs17782313, transmembrane protein 18 [TMEM18]-
rs2867125, SH2B adaptor protein 1 [SH2B1]- rs7498665, brain-
derived neurotrophic factor [BDNF]- rs4074134, potassium
channel tetramerisation domain containing 15 [KCTD15]-
rs29941, ets variant 5 [ETV5]- rs7647305, SEC16 homolog B
[SEC16B]- rs10913469, Fas apoptotic inhibitory molecule 2
[FAIM2]- rs7138803, neuronal growth regulator 1 [NEGR1]-
rs3101336, mitochondrial carrier 2 [MTCH2]- rs10838738, and
glucosamine-6-phosphate deaminase 2 [GNPDA2]- rs10938397)
for our analysis based on the study by Li et al. [24] and previously
published genome-wide association studies for obesity-related
traits [23,25,26]. The four vitamin D-related SNPs (DHCR7-
rs12785878, CYP2R1- rs10741657, GC- rs2282679, and CYP24A1-
rs6013897) were chosen on the basis of the recent genome-wide
association study on 25(OH)D [27]. The studies that did not have
genotyped data analysed imputed or proxy SNPs (r2 = 1) as
available (with a call threshold of 0.9 for the SNPs imputed with
Impute; for those imputed with MACH, a call threshold of 0.8 was
used) [28]. The genetic data for most studies were obtained from
genome-wide association platforms, but for some studies, variants
were genotyped de novo (MRC Ely, the Canadian Multicentre
Osteoporosis Study, the Hertfordshire cohort study) or obtained
through metabochip custom array (MRC Ely). Five studies did not
have all the BMI-related SNPs (Framingham Heart Study [one
missing SNP], Hertfordshire cohort study [three missing SNPs],
InCHIANTI [two missing SNPs], PIVUS [two missing SNPs],
and ULSAM [three missing SNPs]) and were still included in the
BMI allele score analysis. Table S1 shows the minor allele
frequencies for the BMI and vitamin D SNPs that were included in
the analysis. A detailed description of the genotyping methods is
provided in Text S2.
Statistical Analysis
Analyses in each study were performed according to a
standardized analysis plan. When used as outcome variables,
25(OH)D and BMI were natural log transformed to be more
closely approximated by normal distributions. If multiplied by 100,
coefficients from linear regression models with ln transformed
outcomes can be interpreted as the percentage difference in the
outcome [29]. Models with BMI as an outcome were adjusted for
Body Mass Index and 25(OH)D
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age, sex, geographical site, and/or principal components from
population stratification analysis (depending on data available);
models with 25(OH)D as the outcome were additionally adjusted
for month of blood sample collection (as a categorical variable) to
account for seasonal variation and laboratory batch, where
relevant. To assess the BMI relationship with 25(OH)D and vice
versa, each study ran linear regression models adjusting for the
covariates listed for each outcome, and the models were repeated
stratifying by sex.
For the BMI SNPs, the effect allele was the BMI raising allele as
established by Speliotes et al. [23]. We created a weighted score in
each study [30], by multiplying each SNP (coded as 0–2) by a
weight based on its effect size with BMI in the meta-analysis by
Speliotes et al. [23]. The weighted BMI allele score was rescaled
over the sum of weights for the available SNPs in each study to
facilitate interpretation [30]. For the vitamin D SNPs, the effect
allele was the 25(OH)D lowering allele as established by the
SUNLIGHT Consortium [27]. As external weights were not
available and the use of internal weights could bias the
instrumental variable (IV) results [31], we performed an
unweighted allele score analysis for the vitamin D SNPs. Vitamin
D SNPs were used to form two separate allele scores [32]: a
‘‘synthesis’’ allele score, created by summing the risk alleles in
DHCR7 and CYP2R1, and a ‘‘metabolism’’ allele score, created by
summing the risk alleles in GC and CYP24A1 (Figure S1). Synthesis
allele score was not created for the LURIC study (one missing
SNP) and both synthesis and metabolism allele scores were not
created for the MRC Ely study (two missing SNPs). The synthesis
allele score included the SNPs that contribute directly to the
production of 25(OH)D, and hence, for which the association with
the outcome can be readily estimated based on the magnitude of
the association between the score and 25(OH)D [32]. All analyses
were done separately for the ‘‘metabolism’’ SNPs that are involved
in the clearance or transport of 25(OH)D (with possible influences
on bioavailability [33]) as the quantification of the association with
the outcome based on the observed SNP-25(OH)D association is
more difficult [32]. We also evaluated the joint contribution of
synthesis and metabolism scores on BMI by including both
vitamin D scores as separate variables in a multiple regression
model. To examine the strength of the allele scores as instruments,
the F-statistic was approximated from the proportion of variation
in the respective phenotype (R2) explained by the allele score, [F-
stat = (R26(n22))/(12R2)] [34].
To confirm our findings on the association between the vitamin
D-related SNPs and allele scores with BMI in a larger sample, we
used the summary statistics for the four vitamin D-related SNPs
from the GIANT consortium. These SNPs were combined into
synthesis and metabolism allele scores using an approximation
method as previously described [35]. The individual SNP
association with BMI is then weighted according to its predefined
effect size and meta-analysed using the inverse-variance method
with the other SNPs in the score [35]. The formal MR analyses to
estimate the possible causal effect of BMI on 25(OH)D (and vice
versa) were done using the IV ratio method [20,36]. To estimate
the IV ratio for the BMI effect on 25(OH)D, the meta-analysed
association of the BMI allele score with 25(OH)D was divided by
the association of BMI allele score with BMI. The variance for the
IV ratio was estimated using a Taylor expansion [36]. The
corresponding calculation was done to establish the 25(OH)D
effect on BMI, with the IV ratio method applied separately for the
two vitamin D allele scores. The joint contribution of the two
vitamin D scores on BMI was assessed by multivariate meta-
analysis [37], which incorporated the covariance matrix as
estimated by study specific analyses.
In the presence of heterogeneity of association between the
studies, random effects meta-analyses [38] were run, otherwise
fixed effects models were used. Univariate meta-regression models
were run to assess differences in the observed associations by study
level factors of sex, average BMI (BMI#25 kg/m2 versus.25 kg/
m2), the average age of participants (#40, 41–60, and $61 y old),
continent (North America versus Europe), and vitamin D assay
(radio-immunoassay, enzyme-linked radio-immunoassay, and
mass spectrometry). Power calculations for IV regression were
performed by simulation [32] on the basis of associations observed
between the phenotypes and their genetic proxies. For compara-
bility across instruments/outcomes, power was determined for
0.02 log unit increase/decrease by decile, approximately corre-
sponding to the association observed between BMI and 25(OH)D.
To evaluate the ability to detect weaker effects on BMI using the
synthesis and metabolism scores, power was also calculated for a
50% weaker effect (0.01 log unit increase/decrease). All meta-
analyses and power calculations were performed at the Institute of
Child Health (University College London, London) using STATA
version 12 [39].
Figure 1. Random effects meta-analysis of the BMI association
with 25(OH)D in men (A) (n = 20,950) and women (B)
(n= 21,074). 95% confidence intervals given by error bars.
doi:10.1371/journal.pmed.1001383.g001
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Results
Phenotypic Association between BMI and 25(OH)D
Concentrations
In the meta-analyses of 21 studies, each unit (kg/m2) increase in
BMI was associated with 1.15% (95% CI 0.94%–1.36%,
p= 6.52610227) lower concentrations of 25(OH)D after adjusting
for age, sex, laboratory batch, month of measurement, and
principal components. The inverse association between BMI and
25(OH)D was stronger among the studies from North America
than those from Europe (21.58% [21.81% to 21.36%],
p= 1.01610243 versus 20.91% [21.18% to 20.64%],
p= 4.55610211; pmeta-regression = 0.004) and for women than men
(21.43% [21.65% to 21.22%], p= 1.13610238 versus 20.75%
[21.00% to 20.50%], p= 3.8961029; pmeta-regression = 4.10610
24)
while no variation was seen by average age (pmeta-regression = 0.78) or
BMI (pmeta-regression = 0.48) (Figure 1A and 1B).
Evaluation of Causal Association Using MR Approach
The BMI allele score created from the 12 BMI-related SNPs
showed a positive dose-response association with BMI (per unit
increase 0.14% [0.12%–0.16%], p= 6.30610262), and both
vitamin D allele scores showed the expected strong associations
with 25(OH)D (per allele in synthesis score: 23.47% [23.90% to
23.05%], p= 8.07610257; metabolism allele score: 25.38%
[25.84% to 24.93%], p= 1.076102118) (Figures 2, S2, and S3).
The BMI allele score was also associated with 25(OH)D
concentrations (per unit increase 20.06%, [20.10% to
20.02%], p= 0.004) (Figure 3), while no association with BMI
was seen for either the vitamin D synthesis or metabolism allele
scores (per allele in synthesis score: 0.01% [20.17% to 0.20%],
p= 0.88, metabolism allele score: 0.17% [20.02% to 0.35%],
p= 0.08]) (Figure 4A and 4B). Analyses of joint effects by synthesis
and metabolism scores provided no evidence for an association
between 25(OH)D and BMI (per allele in synthesis score 20.03%
[20.23% to 0.16%] and metabolism score 0.17% [20.04% to
0.37%], joint contribution p= 0.26).
In the analyses to establish the direction and causality of BMI–
25(OH)D association by the use of the IV ratio, BMI was
associated with 25(OH)D: each 10% increase in BMI lead to a
4.2% decrease in 25(OH)D concentrations (27.1% to 21.3%;
p= 0.005). However, the IV ratio analyses provided little
evidence for a causal effect of 25(OH)D on BMI (p$0.08 for
both). We have summarised the coefficients for the MR analyses in
Table 2.
The lack of association of the vitamin D allele scores with BMI
was further confirmed using the GIANT consortium including
123,864 individuals in 46 studies [23]: neither the synthesis nor the
metabolism allele score showed any evidence for an association
with BMI (p$0.57 for both) (Table 3).
Figure 2. Meta-analysis of the BMI allele score association with BMI (n= 32,391), and the vitamin D synthesis (n= 35,873) and
metabolism (n= 38,191) allele score association with 25(OH)D. 95% confidence intervals given by error bars.
doi:10.1371/journal.pmed.1001383.g002
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PLOS Medicine | www.plosmedicine.org 6 February 2013 | Volume 10 | Issue 2 | e1001383
Additional Analyses
Validation of the genetic instruments. The BMI SNPs
and the vitamin D SNPs were all individually associated with BMI
and 25(OH)D, respectively (Figures S4 and S5). The exception
was KCTD15 SNP, which despite previous evidence for an
association [25], was not associated with BMI in our meta-
analyses. Across the studies, the 12 BMI SNPs combined as the
BMI allele score explained 0.97% of the variation in BMI (F-
statistic = 316; n= 32,391). The synthesis allele score explained
0.64% (F-statistic = 230; n= 35,873) and the metabolism allele
score 1.26% (F statistic = 489; n= 38,191) of the variation in
25(OH)D. There was no evidence for variation in the BMI allele
score–BMI association by continent (pmeta-regression = 0.15) or BMI
(pmeta-regression = 0.83). However, the BMI allele score–BMI asso-
ciation was slightly weaker in studies with older compared to
younger participants (20.03% [20.05% to 20.002%],
pmeta-regression = 0.03). The vitamin D allele score–25(OH)D
association did not vary by age, BMI, continent, or assay
(pmeta-regression$0.09 for all comparisons).
Evaluation of the genetic outcome associations. Of the
12 individual BMI SNPs, the SNP for FTO was the only one that
showed evidence of a univariate association with 25(OH)D
(p= 0.050) (Figure S6). None of the four 25(OH)D SNPs were
individually associated with BMI (p$0.10) (Figure S7). The lack of
association of the four vitamin D SNPs with BMI was further
confirmed using the summary data from the GIANT consortium
(p.0.30 for all the SNPs) (Table 3).
The association between BMI allele score and 25(OH)D did not
vary by study level factors, including age (pmeta-regression = 0.40), BMI
(pmeta-regression = 0.18), continent of study (pmeta-regression = 0.78), or
vitamin D assay (pmeta-regression = 0.23). Similarly, there was no
evidence for variation in the vitamin D allele score–BMI
association by age (pmeta-regression$0.25 for both scores), or continent
(pmeta-regression$0.50 for both scores). There was also no strong
evidence for variation in the vitamin D allele score–BMI
association by average BMI of the study (#25 kg/m2 versus
$25 kg/m2), although for the synthesis score the meta-regression
coefficient was of borderline significance (pmeta-regression = 0.053,
Figure S8; pmeta-regression = 0.78 for metabolism score).
Power comparison. Illustrative power calculations are pre-
sented in Figure S9. In theory, we had greater power to detect an
association between 25(OH)D and BMI using the metabolism score
as an instrument, compared with an equal sized association between
BMI and 25(OH)D using the BMI risk score. However, if the size of
the association between 25(OH)D and BMI was only half that seen
between BMI and 25(OH)D, our study would not have been
adequately powered even with the inclusion of the GIANT results.
Discussion
Obesity, and perhaps vitamin D deficiency, are among the most
important modifiable risk factors for a number of chronic diseases.
Obesity and vitamin D status are known to be associated but the
direction of the association and whether it is causal has been
uncertain. We have presented genetic evidence that higher BMI
leads to lower vitamin D status. Conversely, our analyses provided
no evidence for a causal role of vitamin D in the development of
obesity, although our study was not powered to detect very small
effects. These results suggest that although increases in vitamin D
status are not likely to help with weight regulation, increased risk
Figure 3. Meta-analysis of the BMI allele score association with 25(OH)D (n= 31,120). 95% confidence intervals given by error bars.
doi:10.1371/journal.pmed.1001383.g003
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of vitamin D deficiency could contribute to the adverse health
effects associated with obesity.
The association between obesity and vitamin D status was
remarkably consistent across the different populations included in
our meta-analyses, being apparent both in men and in women,
and in the young and older cohorts alike. Interestingly, the
association between obesity and 25(OH)D concentrations ap-
peared stronger for populations in North America compared to
Europe, possibly reflecting differences in the distribution of BMI
across the continents. Recent intervention studies have shown that
obese individuals need higher vitamin D dosages than lean
individuals to achieve the same 25(OH)D concentrations [40,41].
Given that North America has one of the highest rates of obesity in
the world [42], our study highlights the importance of considering
obesity as a risk factor for vitamin D deficiency with implications
on the dosage requirements and possible targeting of relevant
health promotion strategies.
The lack of any suggestion for an association between the
vitamin D SNPs and BMI in the GIANT consortium (n= 123,864)
alongside our own large meta-analyses provides a strong case
against linear increases in 25(OH)D having a substantive influence
on BMI. This conclusion is in accordance with a recent study on
Chinese women (n= 7,000), which also failed to observe evidence
for an association with BMI for genetic variants in the vitamin D
pathway [43]. Although a recent RCT (n= 77) suggested greater
loss in fat mass for women receiving vitamin D [15], previous trials
have failed to show any evidence for an effect despite larger
treatment groups (n= 200–445), use of higher vitamin D dosages,
and equal duration of treatment (12 mo) [13,14]. Dilution related
to the greater volume of distribution has been recently proposed as
the most likely explanation for the lower 25(OH)D concentrations
in obese individuals [44]. In that study, no evidence was found for
reduced bioavailability through increased sequestration of vitamin
D in the adipose tissue, which had previously been suggested to
contribute to the low 25(OH)D concentrations in obesity [18]. In
contrast, intact parathyroid hormone (iPTH) levels [45], which
stimulate the 1-a-hydroxylase (CYP27B1) enzyme that converts
25(OH)D to 1,25-dihydroxyvitamin D (the active hormonal form),
have been found to be elevated in obesity [46], which could to
some extent also contribute to the lower 25(OH)D concentrations
in obese individuals. It is also possible that differences in lifestyle
could contribute to lower 25(OH)D concentrations in obese
compared to normal weight individuals, although the association
between obesity and low 25(OH)D concentrations has been found
to only modestly attenuate after adjustment for vitamin D-related
lifestyle and dietary factors [9].
The main strengths of this study are the large sample size and
the individual level population-based data from North America
and Europe. We used a bi-directional MR approach to investigate
the causal directions between obesity and vitamin D deficiency,
observing evidence for reductions in 25(OH)D by BMI but not
vice versa. However, based on the biological pathways proposed, a
possible effect of 25(OH)D on BMI could be expected to be
weaker than the effect of BMI on 25(OH)D. Despite including
data from the large GIANT consortium to narrow the range of
effects compatible with the data, we are unable to exclude very
small effects. Furthermore, while the MR approach enables the
approximation of life-long differences in average concentrations,
with genetic markers it is not possible to examine the influences
arising from the extremes of non-linear distributions [20].
Consequently, we cannot discount a possible effect of severe
vitamin D deficiency on BMI due to evidence of non-linearity seen
in some studies [47]. In contrast, associations between BMI and
25(OH)D within levels in the obesity range were consistently
linear in studies included in our analyses (unpublished data),
hence the observed association between higher BMI and lower
25(OH)D is likely to be informative in the context of obesity.
One of the methodological challenges of the MR approach
relates to the large sample size requirement, arising from the
availability of relatively weak instruments for most exposures
[22,31]. This aspect of the MR approach is also reflected in our
study, notably in the relatively small amount of variation explained
by all the instruments used. We used the IV ratio method on meta-
analyzed coefficients since all studies were not able to share
individual level participant data. This method assumes linear
relationships and may have less power to detect an effect than other
IV methods [48]. However, as shown by the clear outcome of these
analyses, we were able to overcome these issues by combining
several cohorts with comparable information, allowing us to achieve
the large numbers required (maximum n= 42,024) [31]. To confirm
the lack of association between vitamin D-related genetic variations
and BMI, we were able to expand the analyses by using data from
the large GIANT meta-analyses (n= 123,864) [23]. However, this
cannot be considered an independent replication, as eight of the
studies that were part of the D-CarDia Collaboration were also
included in GIANT. The F-statistic is used to measure the strength
of an instrument, and an instrument that has a value greater than 10
is considered strong enough to use in IV analyses [49]. In our
analyses, the F-statistic was greater than 200 for all instruments used
due to our large sample size.
Combining large population-based studies from North America
and Europe could lead to confounding by population stratification;
Figure 4. Meta-analysis of the synthesis allele score association with BMI (A) (n= 36,553) and the metabolism allele score
association with BMI (B) (n= 40,367). 95% confidence intervals given by error bars.
doi:10.1371/journal.pmed.1001383.g004
Table 2. Summary of the coefficients used for IV ratio analyses.
IV
Allele Score with the
Intermediate Trait Allele Score with the Outcome IV Ratioa
Coefficient, % (95% CI) Coefficient,% (95% CI) Coefficient (95% CI) p-Value
BMI risk score 0.14 (0.12–0.16) 20.06 (20.1 to 20.02) 20.42 (20.71 to 20.13) 0.005
Synthesis score 23.47 (23.90 to 23.05) 0.01 (20.17 to 0.20) 20.00 (20.06 to 0.05) 0.88
Metabolism score 25.38 (25.84 to 24.93) 0.17 (20.02 to 0.35) 20.03 (20.06 to 0.01) 0.08
aCalculated as the ratio between the allele score association with the outcome and intermediate trait. Coefficients can be interpreted as percent change in the outcome
by percent change in the intermediate trait.
doi:10.1371/journal.pmed.1001383.t002
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however, we adjusted for geographical variation/principal com-
ponents in all analyses, which appeared adequate, as there was no
evidence for heterogeneity by continent for the allele score meta-
analyses. An important benefit of the MR approach is that it helps
to overcome problems of confounding and reverse causality, which
limit the ability to draw causal inferences in non-genetic
observational studies [19,20]. However, it could be argued that
as the biological function for some of the BMI SNPs is yet to be
established, there could be alternative biological pathways
explaining their association with BMI. Using multiple SNPs to
index BMI, we were able to minimise the risk of pleiotropic effects,
as the effects of alternative pathways reflected by individual SNPs
would be expected to be strongly diluted when combined in a
multi marker score [21,22].
In conclusion, we demonstrated that the association between
BMI and lower 25(OH)D concentrations in Caucasian popula-
tions from North America and Europe can be seen across
different age groups and in both men and women. We also show
that higher BMI leads to lower vitamin D status, providing
evidence for the role of obesity as a causal risk factor for
the development of vitamin D deficiency. Together with the
suggested increases in vitamin D requirements in obese individ-
uals [45,50], our study highlights the importance of monitoring
and treating vitamin D deficiency as a means of alleviating the
adverse influences of excess adiposity on health. Our findings
suggest that population level interventions to reduce obesity
would be expected to lead to a reduction in the prevalence of
vitamin D deficiency.
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rs12785878 DHCR7 0.001 (20.01 to 0.009) 0.78
rs10741657 CYP2R1 20.005 (20.004 to 0.01) 0.30
Synthesis allele score (rs12785878+rs10741657) DHCR7 + CYP2R1 20.002 (20.009 to 0.005)a 0.57
rs2282679 GC 0.001 (20.011 to 0.010) 0.91
rs6013897 CYP24A1 0.003 (20.008 to 0.014) 0.61
Metabolism allele score (rs2282679+rs6013897) GC + CYP24A1 0.002 (20.006 to 0.009)a 0.67
The GIANT meta-analyses consisted of 46 studies with up to 123,865 adults of European ancestry [23], including the 1958 British Birth Cohort, Framingham Heart study,
Nurses’ Health Study, Twins UK, UK Blood Services Common Control Collection, the Amish Family Osteoporosis Study, Health2000 GENMETS sub-sample, and Northern
Finland Birth Cohort 1966, which were also part of the D-CarDia collaboration.
aCalculated as described in Ehret et al. [35].
doi:10.1371/journal.pmed.1001383.t003
Body Mass Index and 25(OH)D
PLOS Medicine | www.plosmedicine.org 10 February 2013 | Volume 10 | Issue 2 | e1001383
Weedon, Eleanor Wheeler, Andrew R Wood, Teresa Ferreira, Robert J
Weyant, Ayellet V Segre`, Karol Estrada, Liming Liang, James Nemesh, Ju-
Hyun Park, Stefan Gustafsson, Tuomas O Kilpela¨inen, Jian Yang, Nabila
Bouatia-Naji, To˜nu Esko, Mary F Feitosa, Zolta´n Kutalik, Massimo
Mangino, Soumya Raychaudhuri, Andre Scherag, Albert Vernon Smith,
Ryan Welch, Jing Hua Zhao, Katja K Aben, Devin M Absher, Najaf
Amin, Anna L Dixon, Eva Fisher, Nicole L Glazer, Michael E Goddard,
Nancy L Heard-Costa, Volker Hoesel, Jouke-Jan Hottenga, A˚sa Johans-
son, Toby Johnson, Shamika Ketkar, Claudia Lamina, Shengxu Li,
Miriam F Moffatt, Richard H Myers, Narisu Narisu, John R B Perry,
Marjolein J Peters, Michael Preuss, Samuli Ripatti, Fernando Rivadeneira,
Camilla Sandholt, Laura J Scott, Nicholas J Timpson, Jonathan P Tyrer,
Sophie van Wingerden, Richard M Watanabe, Charles C White, Fredrik
Wiklund, Christina Barlassina, Daniel I Chasman, Matthew N Cooper,
John-Olov Jansson, Robert W Lawrence, Niina Pellikka, Inga Prokopenko,
Jianxin Shi, Elisabeth Thiering, Helene Alavere, Maria T S Alibrandi,
Peter Almgren, Alice M Arnold, Thor Aspelund, Larry D Atwood,
Beverley Balkau, Anthony J Balmforth, Amanda J Bennett, Yoav Ben-
Shlomo, Richard N Bergman, Sven Bergmann, Heike Biebermann,
Alexandra I F Blakemore, Tanja Boes, Lori L Bonnycastle, Stefan R
Bornstein, Morris J Brown, Thomas A Buchanan, Fabio Busonero, Harry
Campbell, Francesco P Cappuccio, Christine Cavalcanti-Proenc¸a, Yii-Der
Ida Chen, Chih-Mei Chen, Peter S Chines, Robert Clarke, Lachlan Coin,
John Connell, Ian N M Day, Martin den Heijer, Jubao Duan, Shah
Ebrahim, Paul Elliott, Roberto Elosua, Gudny Eiriksdottir, Michael R
Erdos, Johan G Eriksson, Maurizio F Facheris, Stephan B Felix, Pamela
Fischer-Posovszky, Aaron R Folsom, Nele Friedrich, Nelson B Freimer,
Mao Fu, Stefan Gaget, Pablo V Gejman, Eco J C Geus, Christian Gieger,
Anette P Gjesing, Anuj Goel, Philippe Goyette, Harald Grallert, Ju¨rgen
Gra¨ßler, Danielle M Greenawalt, Christopher J Groves, Vilmundur
Gudnason, Candace Guiducci, Anna-Liisa Hartikainen, Neelam Hassa-
nali, Alistair S Hall, Aki S Havulinna, Caroline Hayward, Andrew C
Heath, Christian Hengstenberg, Andrew A Hicks, Anke Hinney, Albert
Hofman, Georg Homuth, Jennie Hui, Wilmar Igl, Carlos Iribarren, Bo
Isomaa, Kevin B Jacobs, Ivonne Jarick, Elizabeth Jewell, Ulrich John,
Torben Jørgensen, Pekka Jousilahti, Antti Jula, Marika Kaakinen, Eero
Kajantie, Lee M Kaplan, Sekar Kathiresan, Johannes Kettunen, Leena
Kinnunen, Joshua W Knowles, Ivana Kolcic, Inke R Ko¨nig, Seppo
Koskinen, Peter Kovacs, Johanna Kuusisto, Peter Kraft, Kirsti Kvaløy,
Jaana Laitinen, Olivier Lantieri, Chiara Lanzani, Lenore J Launer, Cecile
Lecoeur, Terho Lehtima¨ki, Guillaume Lettre, Jianjun Liu, Marja-Liisa
Lokki, Mattias Lorentzon, Robert N Luben, Barbara Ludwig, Paolo
Manunta, Diana Marek, Michel Marre, Nicholas G Martin, Wendy L
McArdle, Anne McCarthy, Barbara McKnight, Thomas Meitinger, Olle
Melander, David Meyre, Kristian Midthjell, Grant W Montgomery, Mario
A Morken, Andrew P Morris, Rosanda Mulic, Julius S Ngwa, Mari Nelis,
Matt J Neville, Dale R Nyholt, Christopher J O’Donnell, Stephen
O’Rahilly, Ken K Ong, Ben Oostra, Guillaume Pare´, Alex N Parker,
Markus Perola, Irene Pichler, Kirsi H Pietila¨inen, Carl G P Platou, Ozren
Polasek, Anneli Pouta, Suzanne Rafelt, Olli Raitakari, Nigel W Rayner,
Martin Ridderstra˚le, Winfried Rief, Aimo Ruokonen, Neil R Robertson,
Peter Rzehak, Veikko Salomaa, Alan R Sanders, Manjinder S Sandhu,
Serena Sanna, Jouko Saramies, Markku J Savolainen, Susann Scherag,
Sabine Schipf, Stefan Schreiber, Heribert Schunkert, Kaisa Silander, Juha
Sinisalo, David S Siscovick, Jan H Smit, Nicole Soranzo, Ulla Sovio,
Jonathan Stephens, Ida Surakka, Amy J Swift, Mari-Liis Tammesoo, Jean-
Claude Tardif, Maris Teder-Laving, Tanya M Teslovich, John R
Thompson, Brian Thomson, Anke To¨njes, Tiinamaija Tuomi, Joyce B J
van Meurs, Gert-Jan van Ommen, Vincent Vatin, Jorma Viikari, Sophie
Visvikis-Siest, Veronique Vitart, Carla I G Vogel, Benjamin F Voight,
Lindsay L Waite, Henri Wallaschofski, G Bragi Walters, Elisabeth Widen,
Susanna Wiegand, Sarah H Wild, Gonneke Willemsen, Daniel R Witte,
Jacqueline C Witteman, Jianfeng Xu, Qunyuan Zhang, Lina Zgaga,
Andreas Ziegler, Paavo Zitting, John P Beilby, I Sadaf Farooqi, Johannes
Hebebrand, Heikki V Huikuri,Alan L James, Mika Ka¨ho¨nen, Douglas F
Levinson, Fabio Macciardi, Markku S Nieminen, Claes Ohlsson, Lyle J
Palmer, Paul M Ridker, Michael Stumvoll, Jacques S Beckmann, Heiner
Boeing, Eric Boerwinkle, Dorret I Boomsma, Mark J Caulfield, Stephen J
Chanock, Francis S Collins, L Adrienne Cupples, George Davey Smith,
Jeanette Erdmann, Philippe Froguel, Henrik Gro¨nberg, Ulf Gyllensten, Per
Hall, Torben Hansen, Tamara B Harris, Andrew T Hattersley, Richard B
Hayes, Joachim Heinrich, Frank B Hu, Kristian Hveem, Thomas Illig,
Marjo-Riitta Jarvelin, Jaakko Kaprio, Fredrik Karpe, Kay-Tee Khaw,
Lambertus A Kiemeney, Heiko Krude, Markku Laakso, Debbie A Lawlor,
Andres Metspalu, Patricia B Munroe, Willem H Ouwehand, Oluf
Pedersen, Brenda W Penninx, Annette Peters, Peter P Pramstaller,
Thomas Quertermous, Thomas Reinehr, Aila Rissanen, Igor Rudan,
Nilesh J Samani, Peter E H Schwarz, Alan R Shuldiner, Timothy D
Spector, Jaakko Tuomilehto, Manuela Uda, Andre´ Uitterlinden, Timo T
Valle, Martin Wabitsch, Ge´rard Waeber, Nicholas J Wareham,Hugh
Watkins, James F Wilson, Alan F Wright, M Carola Zillikens, Nilanjan
Chatterjee, Steven A McCarroll, Shaun Purcell, Eric E Schadt, Peter M
Visscher, Themistocles L Assimes, Ingrid B Borecki, Panos Deloukas,
Caroline S Fox, Leif C Groop, Talin Haritunians, David J Hunter, Robert
C Kaplan, Karen L Mohlke, Jeffrey R O’Connell, Leena Peltonen, David
Schlessinger, David P Strachan, Cornelia M van Duijn, H-Erich
Wichmann, Timothy M Frayling, Unnur Thorsteinsdottir, Gonc¸alo R
Abecasis, Ineˆs Barroso, Michael Boehnke, Kari Stefansson, Kari E North,
Mark I McCarthy, Joel N Hirschhorn, Erik Ingelsson and Ruth J F Loos.
Author Contributions
Conceived and designed the experiments: KSV DJB MM OR JV BDM
EAM NJW TM TL WHO CC TJW MRJ JCW ADH EH. Performed the
experiments: KSV DJB CL ET SP LTH JDC KHL ZD RL ARW KM LZ
LMY JD MCK KJ VS BDM EAS DKH TL PK CC RJFL JCW ADH
EH. Analyzed the data: KSV DJB CL ET SP LTH JDC KHL ZD RL
ARW KM LZ LMY JD MCK KJ VS BDM EAS DKH TL PK CC RJFL
JCW ADH EH. Contributed reagents/materials/analysis tools: KSV DJB
SP LTH KM LMY MM JD MK NA OR JV SBK HM EI LB LL VS
BDM KH EAS DKH TL PK CC WM RJFL CP MRJ JCW ADH EH.
Wrote the first draft of the manuscript: KSV DJB EH. Contributed to the
writing of the manuscript: KSV DJB EH. ICMJE criteria for authorship
read and met: KSV DJB CL ET SP LTH JDC ZD RL DKH ARW KM
LV LZ LMY MM JD MK MEK KJ NA OR JV KKL LF HM EI LB LL
ML VS HC MD BDM KHH AP ALH EAS ET AJ NJW CO TMF SBK
TDS JBR TL WHO PK CC WM CP RJFL TJW MRJ JCW ADH EH.
Agree with manuscript results and conclusions: KSV DJB CL ET SP LTH
JDC ZD RL DKH ARW KM LV LZ LMY MM JD MK MEK KJ NA
OR JV KKL LF HM EI LB LL ML VS HC MD BDM KHH AP ALH
EAS ET AJ NJW CO TMF SBK TDS JBR TL WHO PK CC WM CP
RJFL TJW MRJ JCW ADH EH. Obtained the data: KSV DJB SP LTH
ZD RL KM LV MM MK MCK KJ NA OR JV SBK LF HM EI LB LL
ML VS HC MD BDM AP AH ET NJW CO TMF DKH JBR TL WHO
PK CC WM CP ADH MRJ EH. Provided the administrative, technical, or
material support: KSV DJB KM MK OR JV SBK LF HM EI LL VS
TMF DKH TL CP EH. Supervised the study: JD OR JV SBK HC MD
BDM EAS AJ ET TS TMF JBR TL TJW MRJ JCW ADH EH.
References
1. Baskin ML, Ard J, Franklin F, Allison DB (2005) Prevalence of obesity in the
United States. Obes Rev 6: 5–7.
2. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM (2010) Prevalence
of high body mass index in US children and adolescents, 2007–2008. JAMA
303: 242–249.
3. Berghofer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, et al. (2008)
Obesity prevalence from a European perspective: a systematic review. BMC
Public Health 8: 200.
4. Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, et al. (2011)
Association between body-mass index and risk of death in more than 1 million
Asians. N Engl J Med 364: 719–729.
5. Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and
trends in the distribution of body mass index among US adults, 1999–2010.
JAMA 307: 491–497.
6. Vimaleswaran KS, Loos RJ (2010) Progress in the genetics of common obesity
and type 2 diabetes. Expert Rev Mol Med 12: e7.
Body Mass Index and 25(OH)D
PLOS Medicine | www.plosmedicine.org 11 February 2013 | Volume 10 | Issue 2 | e1001383
7. Ginde AA, Liu MC, Camargo CA, Jr. (2009) Demographic differences and
trends of vitamin D insufficiency in the US population, 1988–2004. Arch Intern
Med 169: 626–632.
8. Lanham-New SA, Buttriss JL, Miles LM, Ashwell M, Berry JL, et al. (2011)
Proceedings of the Rank Forum on vitamin D. Br J Nutr 105: 144–156.
9. Hyppo¨nen E, Power C (2007) Hypovitaminosis D in British adults at age 45 y:
nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr 85:
860–868.
10. Earthman CP, Beckman LM, Masodkar K, Sibley SD (2012) The link between
obesity and low circulating 25-hydroxyvitamin D concentrations: considerations
and implications. Int J Obes (Lond) 36: 387–396.
11. Shi H, Norman AW, Okamura WH, Sen A, Zemel MB (2001) 1alpha,25-
Dihydroxyvitamin D3 modulates human adipocyte metabolism via nongenomic
action. Faseb J 15: 2751–2753.
12. Fassina G, Maragno I, Dorigo P, Contessa AR (1969) Effect of vitamin D2 on
hormone-stimulated lipolysis in vitro. Eur J Pharmacol 5: 286–290.
13. Sneve M, Figenschau Y, Jorde R (2008) Supplementation with cholecalciferol
does not result in weight reduction in overweight and obese subjects.
Eur J Endocrinol 159: 675–684.
14. Zittermann A, Frisch S, Berthold HK, Gotting C, Kuhn J, et al. (2009) Vitamin
D supplementation enhances the beneficial effects of weight loss on
cardiovascular disease risk markers. Am J Clin Nutr 89: 1321–1327.
15. Salehpour A, Shidfar F, Hosseinpanah F, Vafa M, Razaghi M, et al. (2012)
Vitamin D3 and the risk of CVD in overweight and obese women: a randomised
controlled trial. Br J Nutr: 1–8.
16. Soares MJ, Murhadi LL, Kurpad AV, Chan She Ping-Delfos WL, Piers LS
(2012) Mechanistic roles for calcium and vitamin D in the regulation of body
weight. Obes Rev 13: 592–605.
17. Foss YJ (2009) Vitamin D deficiency is the cause of common obesity. Med
Hypotheses 72: 314–321.
18. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF (2000) Decreased
bioavailability of vitamin D in obesity. Am J Clin Nutr 72: 690–693.
19. Davey Smith G, Ebrahim S (2003) ‘Mendelian randomization’: can genetic
epidemiology contribute to understanding environmental determinants of
disease? Int J Epidemiol 32: 1–22.
20. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G (2008)
Mendelian randomization: using genes as instruments for making causal
inferences in epidemiology. Stat Med 27: 1133–1163.
21. Davey Smith G (2011) Random allocation in observational data: how small but
robust effects could facilitate hypothesis-free causal inference. Epidemiology 22:
460–463; discussion 467–468.
22. Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, et al. (2012)
Using multiple genetic variants as instrumental variables for modifiable risk
factors. Stat Methods Med Res 21: 223–242.
23. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, et al. (2010)
Association analyses of 249,796 individuals reveal 18 new loci associated with
body mass index. Nat Genet 42: 937–948.
24. Li S, Zhao JH, Luan J, Luben RN, Rodwell SA, et al. (2010) Cumulative effects
and predictive value of common obesity-susceptibility variants identified by
genome-wide association studies. Am J Clin Nutr 91: 184–190.
25. Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, et al. (2008) Common
variants near MC4R are associated with fat mass, weight and risk of obesity. Nat
Genet 40: 768–775.
26. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, et
al. (2009) Genome-wide association yields new sequence variants at seven loci
that associate with measures of obesity. Nat Genet 41: 18–24.
27. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, et al. (2010)
Common genetic determinants of vitamin D insufficiency: a genome-wide
association study. Lancet 376: 180–188.
28. Zheng J, Li Y, Abecasis GR, Scheet P (2011) A comparison of approaches to
account for uncertainty in analysis of imputed genotypes. Genet Epidemiol 35:
102–110.
29. Cole TJ (2000) Sympercents: symmetric percentage differences on the 100 log(e)
scale simplify the presentation of log transformed data. Stat Med 19: 3109–3125.
30. Lin X, Song K, Lim N, Yuan X, Johnson T, et al. (2009) Risk prediction of
prevalent diabetes in a Swiss population using a weighted genetic score–the
CoLaus Study. Diabetologia 52: 600–608.
31. Pierce BL, Ahsan H, Vanderweele TJ (2011) Power and instrument strength
requirements for Mendelian randomization studies using multiple genetic
variants. Int J Epidemiol 40: 740–752.
32. Berry DJ, Vimaleswaran KS, Whittaker JC, Hingorani AD, Hypponen E (2012)
Evaluation of genetic markers as instruments for mendelian randomization
studies on vitamin D. PLoS One 7: e37465. doi:10.1371/journal.pone.0037465
33. Chun RF, Lauridsen AL, Suon L, Zella LA, Pike JW, et al. (2010) Vitamin D-
binding protein directs monocyte responses to 25-hydroxy- and 1,25-
dihydroxyvitamin D. J Clin Endocrinol Metab 95: 3368–3376.
34. Rice JA (1995) Expected values. Mathematical statistics and data analysis. 2nd
edition. Pacific Grove (California): Duxbury Press.
35. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. (2011) Genetic
variants in novel pathways influence blood pressure and cardiovascular disease
risk. Nature 478: 103–109.
36. Thomas DC, Lawlor DA, Thompson JR (2007) Re: Estimation of bias in
nongenetic observational studies using ‘‘Mendelian triangulation’’ by Bautista et
al. Ann Epidemiol 17: 511–513.
37. White IR (2009) Multivariate random-effects meta-analysis. The Stata Journal 9:
40–56.
38. Borenstein M (2009) Introduction to meta-analysis. Chichester: John Wiley &
Sons. xxviii.
39. StataCorp (2011). Stata Statistical Software: Release 12: College Station (Texas):
StataCorp LP.
40. Jorde R, Sneve M, Emaus N, Figenschau Y, Grimnes G (2010) Cross-sectional
and longitudinal relation between serum 25-hydroxyvitamin D and body mass
index: the Tromso study. Eur J Nutr 49: 401–407.
41. Lee P, Greenfield JR, Seibel MJ, Eisman JA, Center JR (2009) Adequacy of
vitamin D replacement in severe deficiency is dependent on body mass index.
Am J Med 122: 1056–1060.
42. Bassett DR, Jr., Pucher J, Buehler R, Thompson DL, Crouter SE (2008)
Walking, cycling, and obesity rates in Europe, North America, and Australia.
J Phys Act Health 5: 795–814.
43. Dorjgochoo T, Shi J, Gao YT, Long J, Delahanty R, et al. (2012) Genetic
variants in vitamin D metabolism-related genes and body mass index: analysis of
genome-wide scan data of approximately 7000 Chinese women. Int J Obes
(Lond) 36: 1252–1255.
44. Drincic AT, Armas LA, Van Diest EE, Heaney RP (2012) Volumetric dilution,
rather than sequestration best explains the low vitamin D status of obesity.
Obesity (Silver Spring) 20: 1444–1448.
45. Bell NH, Epstein S, Greene A, Shary J, Oexmann MJ, et al. (1985) Evidence for
alteration of the vitamin D-endocrine system in obese subjects. J Clin Invest 76:
370–373.
46. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357: 266–281.
47. Hyppo¨nen E, Berry D, Cortina-Borja M, Power C (2010) 25-Hydroxyvitamin D
and pre-clinical alterations in inflammatory and hemostatic markers: a cross
sectional analysis in the 1958 British Birth Cohort. PLoS One 5: e10801.
doi:10.1371/journal.pone.0010801
48. Burgess S, Thompson SG, Andrews G, Samani NJ, Hall A, et al. (2010) Bayesian
methods for meta-analysis of causal relationships estimated using genetic
instrumental variables. Stat Med 29: 1298–1311.
49. Staiger D, Stock JH (1997) Instrumental variables regression with weak
instruments. Econometrica 65: 557–586.
50. Huh SY, Gordon CM (2008) Vitamin D deficiency in children and adolescents:
epidemiology, impact and treatment. Rev Endocr Metab Disord 9: 161–170.
Body Mass Index and 25(OH)D
PLOS Medicine | www.plosmedicine.org 12 February 2013 | Volume 10 | Issue 2 | e1001383
Editors’ Summary
Background. Obesity—having an unhealthy amount of
body fat—is increasing worldwide. In the US, for example, a
third of the adult population is now obese. Obesity is defined
as having a body mass index (BMI, an indicator of body fat
calculated by dividing a person’s weight in kilograms by their
height in meters squared) of more than 30.0 kg/m2.
Although there is a genetic contribution to obesity, people
generally become obese by consuming food and drink that
contains more energy than they need for their daily
activities. Thus, obesity can be prevented by having a
healthy diet and exercising regularly. Compared to people
with a healthy weight, obese individuals have an increased
risk of developing diabetes, heart disease and stroke, and
tend to die younger. They also have a higher risk of vitamin
D deficiency, another increasingly common public health
concern. Vitamin D, which is essential for healthy bones as
well as other functions, is made in the skin after exposure to
sunlight but can also be obtained through the diet and
through supplements.
Why Was This Study Done? Observational studies cannot
prove that obesity causes vitamin D deficiency because
obese individuals may share other characteristics that reduce
their circulating 25-hydroxy vitamin D [25(OH)D] levels
(referred to as confounding). Moreover, observational studies
cannot indicate whether the larger vitamin D storage
capacity of obese individuals (vitamin D is stored in fatty
tissues) lowers their 25(OH)D levels or whether 25(OH)D
levels influence fat accumulation (reverse causation). If
obesity causes vitamin D deficiency, monitoring and treating
vitamin D deficiency might alleviate some of the adverse
health effects of obesity. Conversely, if low vitamin D levels
cause obesity, encouraging people to take vitamin D
supplements might help to control the obesity epidemic.
Here, the researchers use bi-directional ‘‘Mendelian random-
ization’’ to examine the direction and causality of the
relationship between BMI and 25(OH)D. In Mendelian
randomization, causality is inferred from associations be-
tween genetic variants that mimic the influence of a
modifiable environmental exposure and the outcome of
interest. Because gene variants do not change over time and
are inherited randomly, they are not prone to confounding
and are free from reverse causation. Thus, if a lower vitamin
D status leads to obesity, genetic variants associated with
lower 25(OH)D concentrations should be associated with
higher BMI, and if obesity leads to a lower vitamin D status,
then genetic variants associated with higher BMI should be
associated with lower 25(OH)D concentrations.
What Did the Researchers Do and Find? The researchers
created a ‘‘BMI allele score’’ based on 12 BMI-related gene
variants and two ‘‘25(OH)D allele scores,’’ which are based on
gene variants that affect either 25(OH)D synthesis or
breakdown. Using information on up to 42,024 participants
from 21 studies, the researchers showed that the BMI allele
score was associated with both BMI and with 25(OH)D levels
among the study participants. Based on this information,
they calculated that each 10% increase in BMI will lead to a
4.2% decrease in 25(OH)D concentrations. By contrast,
although both 25(OH)D allele scores were strongly associat-
ed with 25(OH)D levels, neither score was associated with
BMI. This lack of an association between 25(OH)D allele
scores and obesity was confirmed using data from more than
100,000 individuals involved in 46 studies that has been
collected by the GIANT (Genetic Investigation of Anthropo-
metric Traits) consortium.
What Do These Findings Mean? These findings suggest
that a higher BMI leads to a lower vitamin D status whereas
any effects of low vitamin D status on BMI are likely to be
small. That is, these findings provide evidence for obesity as
a causal factor in the development of vitamin D deficiency
but not for vitamin D deficiency as a causal factor in the
development of obesity. These findings suggest that
population-level interventions to reduce obesity should lead
to a reduction in the prevalence of vitamin D deficiency and
highlight the importance of monitoring and treating vitamin
D deficiency as a means of alleviating the adverse influences
of obesity on health.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001383.
N The US Centers for Disease Control and Prevention
provides information on all aspects of overweight and
obesity (in English and Spanish); a data brief provides
information about the vitamin D status of the US
population
N The World Health Organization provides information on
obesity (in several languages)
N The UK National Health Service Choices website provides
detailed information about obesity and a link to a personal
story about losing weight; it also provides information
about vitamin D
N The International Obesity Taskforce provides information
about the global obesity epidemic
N The US Department of Agriculture’s ChooseMyPlate.gov
website provides a personal healthy eating plan; the
Weight-control Information Network is an information
service provided for the general public and health
professionals by the US National Institute of Diabetes
and Digestive and Kidney Diseases (in English and Spanish)
N The US Office of Dietary Supplements provides information
about vitamin D (in English and Spanish)
N MedlinePlus has links to further information about obesity
and about vitamin D (in English and Spanish)
N Wikipedia has a page on Mendelian randomization (note:
Wikipedia is a free online encyclopedia that anyone can
edit; available in several languages)
N Overview and details of the collaborative large-scale
genetic association study (D-CarDia) provide information
about vitamin D and the risk of cardiovascular disease,
diabetes and related traits
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